BioSpace News Archive

Xencor, Inc. announced that company management will participate in two upcoming conferences

Aduro Biotech, Inc. announced that the company earned a $10.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase 2 clinical trial of MK-5890, an anti-CD27 agonist, in non-small cell lung cancer.

ADMA Biologics, Inc. an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, announced that it has commenced an $75 million underwritten public offering of its common stock.

Border Therapy Services and Alliance Physical Therapy Partners are pleased to announce the opening of their new outpatient rehabilitation clinic located at 1300 Murchison Drive.

Mettler-Toledo International Inc. announced fourth quarter results for 2019.

Precision Optics Corporation, Inc. announced that it has scheduled a conference call to discuss second quarter of fiscal 2020 financial results on Thursday, February 13, 2020 at 5:00pm ET.

Illumina, Inc. announced that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates and a resident fellow at the American Enterprise Institute.

Myomo, Inc. announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2019.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2019 financial results after the market close on Thursday, February 27, 2020.

Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will be presenting at the following investor conferences in February